Pharmaceutical News

RSS

Normal synaptic activity in nerve cells protects brain from Huntington's disease

Investigators at Burnham Institute for Medical Research (Burnham), the University of British Columbia's Centre for Molecular Medicine and Therapeutics and the University of California, San Diego have found that normal synaptic activity in nerve cells (the electrical activity in the brain that allows nerve cells to communicate with one another) protects the brain from the misfolded proteins associated with Huntington's disease.

16 Nov 2009

Potential of the European Biomarker Analysis Market to be the focus at upcoming Analyst Briefing

The "omics" revolution of the last decade has ensured that the field of biomarker research will test the frontiers of biomedical research in the coming years. New biomarkers are discovered each day and this rapid development promises excellent growth potential for the biomarker analysis market. However, due to various challenges faced in biomarker validation and assay development, there is a huge lag between the time that a biomarker is discovered in the laboratory and the time it is actually commercialized.

16 Nov 2009

Some combination drug therapies are counter-productive

Combination drug therapy has become a staple for treating many infections. For instance, doctors treat extensively drug resistant forms of tuberculosis with one drug that breaks down the pathogen's protective barriers and opens the door for another to deliver the deathblow.

16 Nov 2009

Department of Health to conduct statewide clinics to administer free H1N1 vaccine

The Department of Health today announced it will conduct statewide clinics from Nov. 20-22 to administer free H1N1 vaccine to individuals in the recommended target groups that have not had previous access to the vaccine.

16 Nov 2009

New reversible oral anti-platelet medication had fewer cardiac events in heart attack patients

Acutely ill heart attack patients who received both aspirin and a new reversible oral anti-platelet medication had fewer cardiac events than patients on aspirin and the most commonly used, irreversible anti-platelet drug, researchers reported in a late-breaking clinical trial presentation at the American Heart Association's Scientific Sessions 2009.

16 Nov 2009

Chronic pain patients with depression three times more likely to receive opioid medications

Chronic pain patients with a history of depression are three times more likely to receive long-term prescriptions for opioid medications like Vicodin compared to pain patients who do not suffer from depression, according to new research.

16 Nov 2009

TIME examines efforts to combat malaria resistance along Thai-Cambodia border

TIME reports on evidence along the Thai-Cambodia border that the malaria parasite is gaining resistance to artemisinin - "the only remaining effective drug in the world's arsenal against malaria's most deadly strain."

16 Nov 2009

Merck to market and develop cardiovascular medicines for a range of cardiovascular disorders

Following the completion of its merger with Schering-Plough, Merck today confirms and underscores its commitment to marketing and developing cardiovascular medicines for a range of cardiovascular disorders.

16 Nov 2009

Phase I clinical study for ETC-1002 commenced

Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced that the company has initiated a Phase I clinical study for ETC-1002, the company's novel small molecule compound designed to beneficially regulate the levels of plasma lipids and lipoproteins.

16 Nov 2009

Priority Review of the NDA for intravenous acetaminophen extended by three months

Cadence Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for its Priority Review of the New Drug Application (NDA) for intravenous (IV) acetaminophen by three months.

15 Nov 2009

$1.2 million federal grant to University of Illinois for botanical dietary supplements research

The University of Illinois at Chicago has received a two-year, $1.2 million federal grant to develop a new method to identify the contents of botanical dietary supplements and how they work.

13 Nov 2009

Medicare Part D program exceeds expectations, majority of seniors approve their plan and coverage

Almost four years after the Medicare Part D prescription drug program went into effect, an overwhelming majority (88 percent) of America's seniors approve of their individual plan and coverage. In a national survey released this morning by the nonpartisan Medicare Today Coalition, 95 percent of seniors who used their plan and received prescriptions over the past year also reported that their plan has worked well, while 85 percent continue to find their monthly premium to be affordable.

13 Nov 2009

Pharmacyclics to present clinical updates and posters relating to PCI-24781 and PCI-32765

Pharmacyclics, Inc. today announced that posters related to PCI-24781 and PCI-32765 have been selected for presentation at the 51st Annual Meeting of the American Society of Hematology (ASH), December 5-8, 2009 in New Orleans, LA.

13 Nov 2009

Axelar AB to present data from ongoing Phase I/II clinical trial of AXL1717

Axelar AB today announced that promising data from the ongoing Phase I/II clinical trial concerning their lead anticancer product AXL1717, an insulin-like growth factor-1 (IGF-1) receptor inhibitor, will be presented next week at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, Massachusetts, USA.

13 Nov 2009

Shire announces findings from Phase 3 study data with Vyvanse

Shire plc, the global specialty biopharmaceutical company, announced findings from a post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse®. In this study, Vyvanse demonstrated significant improvement in Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms as measured by the ADHD Rating Scale IV (ADHD-RS IV) and Connors' Parent Rating Scale-Revised Short (CPRS-RS) in children with ADHD aged 6 to 12 years.

13 Nov 2009

Idaho's U.S. Representatives oppose HR 3962: AARP disappointed

AARP is disappointed Idaho's U.S. Representatives chose to oppose the legislation, ignoring the worsening health care crisis in their home state.

13 Nov 2009

Health Canada approves ONGLYZA for type 2 diabetes treatment

Bristol-Myers Squibb Canada and AstraZeneca Canada today announced that Health Canada has approved ONGLYZA(TM) (saxagliptin) which improves all three key measures of glycemic control - hemoglobin A1c (A1c), fasting plasma glucose (FPG) and post-prandial glucose (PPG) - when taken in combination with other commonly used oral anti-diabetic agents (metformin or a sulfonylurea).

13 Nov 2009

Vanderbilt University researchers study role of statins in reducing flu-related deaths

Vanderbilt University Medical Center researchers are studying statins, the class of drugs long associated with lowering cholesterol, as a way to reduce H1N1-related deaths.

13 Nov 2009

CSL's H1N1 influenza vaccine receives approval from FDA for use in children ages 6 months and older

The U.S. Food and Drug Administration has approved the use of the CSL Limited's 2009 H1N1 influenza vaccine to include children ages 6 months and older. This vaccine was previously approved only for use in adults, ages 18 years and older.

13 Nov 2009

Nutra Pharma to market its OTC pain reliever in Brazil and Colombia, begins the drug registration process

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it plans to begin the drug registration process in Brazil and Colombia for its over-the-counter (OTC) pain reliever. The company is currently marketing a similar drug in the United States under the brand name Cobroxin for the treatment of moderate to severe (Stage 2) chronic pain.

13 Nov 2009

Pharmaceutical News

Normal synaptic activity in nerve cells protects brain from Huntington's disease

Potential of the European Biomarker Analysis Market to be the focus at upcoming Analyst Briefing

Some combination drug therapies are counter-productive

Department of Health to conduct statewide clinics to administer free H1N1 vaccine

New reversible oral anti-platelet medication had fewer cardiac events in heart attack patients

Chronic pain patients with depression three times more likely to receive opioid medications

TIME examines efforts to combat malaria resistance along Thai-Cambodia border

Merck to market and develop cardiovascular medicines for a range of cardiovascular disorders

Phase I clinical study for ETC-1002 commenced

Priority Review of the NDA for intravenous acetaminophen extended by three months

$1.2 million federal grant to University of Illinois for botanical dietary supplements research

Medicare Part D program exceeds expectations, majority of seniors approve their plan and coverage

Pharmacyclics to present clinical updates and posters relating to PCI-24781 and PCI-32765

Axelar AB to present data from ongoing Phase I/II clinical trial of AXL1717

Shire announces findings from Phase 3 study data with Vyvanse

Idaho's U.S. Representatives oppose HR 3962: AARP disappointed

Health Canada approves ONGLYZA for type 2 diabetes treatment

Vanderbilt University researchers study role of statins in reducing flu-related deaths

CSL's H1N1 influenza vaccine receives approval from FDA for use in children ages 6 months and older

Nutra Pharma to market its OTC pain reliever in Brazil and Colombia, begins the drug registration process

How does norepinephrine influence anxiety-related behaviours?

Transforming Lab Workflows with Cell Culture Automation

Building Bridges to Scalable Allogeneic Cell Therapy

Latest News